The chemical increased the susceptibility of HCC cells to 5‐FU and reduced drug resistance in 5‐FU‐resistant HCC cells. Network pharmacological research indicated that salvigenin may influence the PI3K/AKT. The gene discussed is PIK3CA; the disease is hepatocellular carcinoma.